Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Rubin

Showing results (71-80 of 785) with videos related to

Pageof 79
Sort By:
Expert Review of Gastroenterology & Hepatology|January 27, 2016
Vedolizumab in the treatment of Crohn's diseaseDino Tarabar, Ayal Hirsch, David T Rubin
The Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique|December 14, 2004
When breastfeeding mothers need CNS-acting drugsEvelyn T Rubin, Amy Lee, Shinya Ito
PLOS Mental Health|February 9, 2026
The puzzle of pain and its psychological implications: Differentiating complex regional pain syndrome from somatic symptom disorderPaul D C Zimmer, Robert T Rubin
Intestinal Research|March 13, 2024
The evolving understanding of histology as an endpoint in ulcerative colitisShintaro Akiyama, Yusuke Miyatani, David T Rubin
Inflammatory Bowel Diseases|July 22, 2015
U.S. Patients with Ulcerative Colitis Do Not Have a Decreased Risk of DiverticulosisJami Kinnucan, Justin Tomal, David T Rubin
Gastroenterology & Hepatology|May 7, 2014
Ethical considerations for clinical trials in inflammatory bowel diseaseDavid T Rubin, Samuel Becker, Mark Siegler
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|May 13, 2024
Impact of a health-system specialty pharmacy on time to upadacitinib initiationDavid Choi, David T Rubin, Bernice Man
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 7, 2000
Temporal expression of the chondrogenic and angiogenic growth factor CYR61 during fracture repairM Hadjiargyrou, W Ahrens, C T Rubin
Plos One|April 21, 2017
Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United StatesHaridarshan Patel, Trevor Lissoos, David T Rubin
Inflammatory Bowel Diseases|February 24, 2012
Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims dataDavid T Rubin, Ozgecan Uluscu, Robert Sederman
Pageof 79

Showing results (71-80 of 785) with videos related to

Sort By:
Pageof 79
Expert Review of Gastroenterology & Hepatology|January 27, 2016
Vedolizumab in the treatment of Crohn's diseaseDino Tarabar, Ayal Hirsch, David T Rubin
The Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique|December 14, 2004
When breastfeeding mothers need CNS-acting drugsEvelyn T Rubin, Amy Lee, Shinya Ito
PLOS Mental Health|February 9, 2026
The puzzle of pain and its psychological implications: Differentiating complex regional pain syndrome from somatic symptom disorderPaul D C Zimmer, Robert T Rubin
Intestinal Research|March 13, 2024
The evolving understanding of histology as an endpoint in ulcerative colitisShintaro Akiyama, Yusuke Miyatani, David T Rubin
Inflammatory Bowel Diseases|July 22, 2015
U.S. Patients with Ulcerative Colitis Do Not Have a Decreased Risk of DiverticulosisJami Kinnucan, Justin Tomal, David T Rubin
Gastroenterology & Hepatology|May 7, 2014
Ethical considerations for clinical trials in inflammatory bowel diseaseDavid T Rubin, Samuel Becker, Mark Siegler
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|May 13, 2024
Impact of a health-system specialty pharmacy on time to upadacitinib initiationDavid Choi, David T Rubin, Bernice Man
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 7, 2000
Temporal expression of the chondrogenic and angiogenic growth factor CYR61 during fracture repairM Hadjiargyrou, W Ahrens, C T Rubin
Plos One|April 21, 2017
Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United StatesHaridarshan Patel, Trevor Lissoos, David T Rubin
Inflammatory Bowel Diseases|February 24, 2012
Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims dataDavid T Rubin, Ozgecan Uluscu, Robert Sederman
Pageof 79